CeriBell, Inc. (CBLL) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Liquidity strength ⢠Ongoing losses ⢠Cash burn CBLL has a strong balance sheet and high gross margin, but persistent operating losses, ongoing cash burn, and a rich valuation make the stock look risky despite its liquidity cushion.
Price Behavior
Key Price Behavior Insights: ⢠Higher-low uptrend ⢠Breakout holding ⢠Near-term stall Support Level: $20.5 to $20.7 Resistance Level: $21.33 CBLL has shown a constructive uptrend over the last month with higher highs and higher lows, staying above the recent breakout zone, though momentum has cooled near $21.33 and a pullback toward support is possible.
Sentiment & News
Key News Insights: ⢠Scheduled release ⢠No new guidance ⢠Limited impact Ceribell's latest update is simply a scheduled Q1 2026 earnings release and conference call on May 11, offering no new operational or guidance details.
AI Summary
CBLL has moved from an early promise story to a real commercialization story, but the investment now hinges on whether deeper utilization within the installed base can outpace ongoing cash burn and rising operating expenses fast enough to convert strong gross margins and revenue growth into operating leverage.
Description
CeriBell, Inc. develops point-of-care EEG technology that uses AI to support detection and management of neurological conditions in acute care settings. Its Ceribell System pairs a bedside EEG platform with disposable headbands and portable recorders to enable rapid monitoring outside traditional neurodiagnostic labs. The company was incorporated in 2014, changed its name from Brain Stethoscope, Inc. in 2015, and is based in Sunnyvale, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 12 | Dec 19 | CBLL | CeriBell, Inc. | Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential. | Closed | +1.2% |